PECA Labs’ Dr. Arush Kalra Named to Pittsburgh’s 40 Under 40 List
PECA Labs, a medical device company redefining the field of vascular grafts and valves with durable, polymeric cardiovascular devices designed to fit, grow, and last, today announced that Co-founder and Chief Scientific Officer Dr. Arush Kalra has been named to the Pittsburgh 40 Under 40 list by Pittsburgh Magazine and PUMP.
PECA Labs Adds Joseph E. Bavaria, MD to Board of Directors
PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has added Joseph E. Bavaria, MD to its board of directors. Dr. Bavaria, an internationally renowned cardiac and thoracic surgeon and an expert in repairing and replacing cardiac valves, will provide key leadership to PECA as it continues to develop and commercialize cardiovascular implants based on its novel tunable polymeric material platform.
PECA Labs Receives Expanded CE Mark for exGraft Family of Vascular Grafts, Allowing for Expandability Designed to Match Growth or Help Avoid Restenosis
PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has received an additional CE Mark for its exGraft family of vascular grafts, expanding its on-label use. exGraft vascular grafts are intended for use as vascular prostheses for replacement or bypass of diseased or injured vessels, and with the new clearance, exGraft now includes instructions for post-operative expansion up to 140 percent with the use of oversized balloon catheters.
Cardiovascular Implant Company PECA Labs Names Three New Board Members
PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has announced it has added Dr. Jeffrey P. Carpenter, Jeffrey O’Donnell, Sr. and Samuel E. Navarro to its board of directors. The new board members will help guide the company as it develops and commercializes cardiovascular implants based on its novel tunable polymeric material platform.
PECA Labs Achieves Successful First-In-Human Implant of the MASA Valve Pediatric Pulmonary Valved Conduit in U.S. Clinical Trial
PECA Labs, a medical device company reimagining vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, today announced the successful first-in-human implant of the MASA Valve. Designed for pediatrics, the MASA Valve is a polymeric valved conduit for pulmonary valve reconstruction. The novel polymeric valve previously received Humanitarian Use Device (HUD) and Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). The company has begun enrollment for the study at four clinical sites in the U.S. as part of its MASA Valve Early Feasibility Clinical Study (MVEFS).
